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Abstract
Natural killer (NK) cells are functionally suppressed in the glioblastoma multiforme (GBM) tumor 
microenvironment. We have recently shown that survival and differentiation of cancer stem-like 
cells (CSCs)/poorly differentiated tumors are controlled through two distinct phenotypes of 
cytotoxic and non-cytotoxic/split anergized NK cells, respectively. In this paper, we studied the 
function of NK cells against brain CSCs/poorly differentiated GBM and their NK cell-
differentiated counterparts. Brain CSCs/poorly differentiated GBM, differentiated by split 
anergized NK supernatants (supernatants from NK cells treated with IL-2 + anti-CD16mAb) 
expressed higher levels of CD54, B7H1 and MHC-I and were killed less by the NK cells, whereas 
their CSCs/poorly differentiated counterparts were highly susceptible to NK cell lysis. Resistance 
to NK cells and differentiation of brain CSCs/poorly differentiated GBM by split anergized NK 
cells were mediated by interferon (IFN)-γ and tumor necrosis factor (TNF)-α. Brain CSCs/poorly 
differentiated GBM expressed low levels of TNFRs and IFN-γRs, and when differentiated and 
cultured with IL-2-treated NK cells, they induced increased secretion of pro-inflammatory 
cytokine interleukin (IL)-6 and chemokine IL-8 in the presence of decreased IFN-γ secretion. NK-
induced differentiation of brain CSCs/poorly differentiated GBM cells was independent of the 
function of IL-6 and/or IL-8. The inability of NK cells to lyse GBM tumors and the presence of a 
sustained release of pro-inflammatory cytokines IL-6 and chemokine IL-8 in the presence of a 
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decreased IFN-γ secretion may lead to the inadequacy of NK cells to differentiate GBM CSCs/
poorly differentiated tumors, thus failing to control tumor growth.
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Introduction
Patients diagnosed with glioblastoma multiforme (GBM) have a poor prognosis and 
therefore, there is an urgent need for the development of novel immunotherapeutics to 
combat this disease. GBM contains stem-like populations, known as cancer stem-like cells 
(CSCs), which are capable of self-renewal, and sustains tumor growth. CSCs and poorly 
differentiated GBMs have developed mechanisms to resist chemo- and radiotherapy by 
increasing DNA mismatch repair and multidrug resistance genes [1, 2]. Several studies have 
also demonstrated detection of IL-6 and IL-8 in the GBM microenvironment [3–9]. A 
correlation between the differentiation status of tumor CSCs and their therapeutic outcome 
has been shown previously [10].
Recently, T cell-based immunotherapy failed to reveal a sufficient clinical benefit, perhaps 
because of a decreased MHC-I expression on GBM cells [11, 12]. NK cells are prime 
candidates for targeting and lysing tumor cells with no or lower MHC-I expression. It has 
been demonstrated that NK cells are present in the human brain and central nervous system 
of patients suffering from multiple sclerosis [13, 14] and also in non-pathological brain 
conditions [15], and have significant influence in maintaining the balance in immune 
regulation. Furthermore, NK cell administration as an adjuvant therapy was shown to reduce 
GBM growth resulting in increased survival in preclinical animal models [16]. 
Consequently, NK cell-based immunotherapy may become a promising strategy for GBM 
patients.
Immunosuppression and escape from immune surveillance are key factors contributing to 
tumor progression [17–20]. Thus, the precise mechanism of NK cell inactivation in the 
GBM microenvironment must be fully elucidated in order to develop effective therapeutic 
strategies.
Castriconi et al. [21, 22] have shown that GBM cells derived from patients are poorly 
differentiated and have stem cell properties. Our previous studies have demonstrated that 
NK-sensitive tumor cells induce “split anergy” in NK cells, a term coined by our laboratory 
[23–29]. We observed that IL-2-activated NK cells lose the ability to mediate cytotoxicity 
and down-modulate CD16 receptor expression, but secrete IFN-γ when triggered by NK 
cell-sensitive tumors [23–29]. In contrast, NK-resistant tumor cells neither induce CD16 
receptor down-modulation nor cause split anergy in NK cells [25, 26]. Decreased NK cell 
cytotoxicity and down-modulation of CD16 receptors on the surface of NK cells have been 
observed in patients with cancer [30, 31]. Our previous research has also demonstrated that 
split anergy can be induced in NK cells treated with IL-2 and anti-CD16mAb [24, 28, 29]. In 
addition, we have shown that increased NK cell cytotoxicity and augmented secretion of 
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IFN-γ were observed against oral squamous carcinoma stem cells (OSCSCs) which 
displayed CSC properties, including high CD44 and low MHC-I, CD54 and B7 homolog 1 
(B7H1) expression [32].
Based on our data obtained from a number of tumor types, we have established that 
cytotoxic NK cells target and kill stem-like cancer cells, while split anergized NK cells 
promote tumor cell differentiation. Tumor differentiation by split anergized NK cells inhibits 
tumor growth, increases MHC-I, CD54 and B7H1 surface expression and results in the 
resistance of differentiated tumors to NK cell-mediated cytotoxicity [10]. We have also 
demonstrated that NK cells were able to lyse healthy stem cells significantly more than their 
differentiated counterparts [32].
In this study, we analyzed the interaction of NK cells with GBM CSCs/poorly differentiated 
tumors. Overall, our data indicate that NK cells target and differentiate GBM CSCs/poorly 
differentiated tumors. However, sustained release of pro-inflammatory cytokines IL-6 and 
IL-8 by GBM in the presence of decreased IFN-γ secretion from interacting NK cells and 
inactivation of NK cell cytotoxic function may lead to GBM CSC survival and suboptimal 
tumor differentiation, resulting in sustained inflammation and progression of cancer.
Materials and methods
Cell lines, reagents and antibodies
RPMI 1640 medium supplemented with 10 % fetal bovine serum (FBS) (Gemini Bio-
Product) was used for human NK cells, monocytes and OSCSC cultures. OSCSCs were 
isolated from oral cancer patients with tongue tumors at UCLA. U87 glioma cell line was 
cultured in DMEM medium supplemented with 10 % FBS, 1 % nonessential amino acids, 
1 % sodium pyruvate, 1 % antibiotic/antimycotic and 1 % L-glutamine. X01GB and X02GB 
GBM CSCs were isolated from freshly resected human tumor tissues [33, 34] and were 
cultured under conditions that allow propagation of brain CSCs as described previously [21, 
35]. Human recombinant IL-2 was obtained from NIH-BRB. Human recombinant tumor 
necrosis factor alpha (hrTNF-α) and interferon gamma (hrIFN-γ) were purchased from 
Biolegend. Monoclonal antibodies to TNF-α were purified in our laboratory from ascites of 
mice injected with TNF-α hybridomas. Polyclonal IFN-γ, IL-6 and IL-8 antibodies were 
prepared in rabbits and purified. Specificity of the antibodies was determined with ELISA 
and functional assays against hrTNF-α, hrIFN-γ, IL-6 and IL-8. 1:100 dilutions of anti-
TNF-α, anti-IFN-γ, anti-IL-6 and anti-IL-8 antibodies were found to be the optimal 
concentration to block the cytokine function. Human recombinant IL-6 and IL-8 were 
purchased from Biolegend and PeproTech, respectively. PE-conjugated antibodies for CD44, 
CD54, B7H1, CD16, TNF-αR, MHC class I polypeptide-related sequence A (MICA), killer 
cell lectin-like receptor subfamily G member 1 (KLRG1) and IFN-γR were purchased from 
Biolegend. Anti-MHC class I antibody was prepared in our laboratory and used at 1:100 
dilution and purified mouse anti-human UL16-binding protein (ULBP) 1–6 antibodies were 
purchased from R&D Systems. Secondary PE-conjugated goat anti-mouse antibody was 
used (Biolegend). Propidium iodide (PI) was purchased from Sigma-Aldrich.
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Purification of NK cells and monocytes
NK cells and monocytes were purified from healthy donors using negative isolation kits 
from stem cell technologies as described previously [25]. Monocytes were irradiated at 20 
Gy. Written informed consents approved by UCLA Institutional Review Board (IRB) were 
obtained from the blood donors, and all procedures were approved by the UCLA-IRB.
Preparation of split anergized NK supernatants and differentiation of OSCSCs, X01GB and 
X02GB cells
Freshly purified NK cells were treated with the combination of anti-CD16mAb (3 μg/mL) 
and IL-2 (1000 units/mL) for 18–24 h, then split anergized NK cell supernatants were 
harvested, and IFN-γ concentration in supernatants was determined using IFN-γ ELISA 
(Biolegend). Poorly differentiated tumor cells were differentiated using increasing amounts 
of split anergized NK cell supernatants added on a daily basis. Split anergized NK cell 
supernatants containing 1000 pg of IFN-γ were required to induce differentiation of 1 × 106 
OSCSCs while 35,000 pg of IFN-γ was needed to differentiate 1 × 106 X01GB and X02GB 
over the course of 5–7 days. Differentiation status of each cell type was evaluated based on 
their susceptibility to NK cell-mediated cytotoxicity and surface expression of CD54, B7H1, 
MHC-I and CD44.
ELISA
IFN-γ, IL-6 and IL-8 (Biolegend) measurements were performed using single ELISAs as 
described previously [25].
Surface staining and cell death assays
As previously described, cells were stained with fluoro-chrome-conjugated antibodies or PI, 
followed by analysis using EPICS XL cytometer and FlowJo software (Tree Star) [24, 25, 
36].
51Cr release cytotoxicity assay
The 51Cr release assay was performed as described previously [37], and the (lytic unit) LU 
30/106 was calculated by using the inverse of the number of effector cells needed to lyse 
30 % of target cells X100.
Statistical analysis
An unpaired, two-tailed student t-test was performed for the statistical analysis.
Results
NK cells were cytotoxic and secreted IFN-γ when cultured with X02GB CSCs/
undifferentiated tumors
X02GB tumors were found to form neuronal sphere-like aggregates and were 
immunoreactive with the neural progenitor markers, nestin and musashi-1 [34, 38]. X02GB 
also expressed common cancer stem cell marker CD133 [35, 38, 39]. These cells formed 
tumors in the brain of immunodeficient mice with high proliferative capacity [34,35]. U87 
Kozlowska et al. Page 4
Cancer Immunol Immunother. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cell line was chosen as the control based on the previous characterization [35]. U87 cells 
were found to have low ability to generate spheroids, colony formation and migration [40]. 
Although U87 expressed CD44, unlike X02GB, no expression of CD133, nestin, SRY (sex 
determining region Y)-box 2 (SOX-2) and musashi-1 could be detected [40].
IL-2-activated NK cells were able to lyse X02GB significantly more than U87 GBM cells 
(Fig. 1a), and they were also able to induce significant secretion of IFN-γ (Fig. 1b). 
Interestingly, even untreated NK cells were able to kill X02GB more than U87; however, no 
secretion of IFN-γ was observed in either culture. A significant decrease in cytotoxicity 
could be observed when NK cells were treated with the combination of IL-2 and anti-
CD16mAb (this condition induces split anergy in NK cells), as compared to IL-2-treated NK 
cells cultured with X02GB and U87 (Fig. 1a). In contrast, the level of IFN-γ secretion was 
significantly higher by split anergized NK cells when compared to IL-2-induced secretion of 
IFN-γ by NK cells co-cultured with and without X02GB and U87 (Fig. 1b). Anti-
CD16mAb-treated NK cells lost significant cytotoxicity and were unable to trigger IFN-γ 
secretion (Fig. 1). IL-2-treated NK cells in the absence of brain tumors also secreted IFN-γ; 
however, the levels were lower than those secreted by IL-2-treated NK cells cultured with 
either U87 or X02GB (Fig. 1b). Split anergized NK cells secreted significantly higher levels 
of IFN-γ in the absence of tumors and the levels increased even more when cultured with 
either U87 or X02GB CSCs (Fig. 1b).
X02GB tumors treated with supernatants from split anergized NK cells were killed less by 
NK cells
When X02GB cells were differentiated with split anergized NK cell supernatants and then 
tested against freshly isolated NK cells, a significantly decreased susceptibility to NK cell-
mediated cytotoxicity was observed (P < 0.05) (Fig. 2a). Supernatants from IL-2-treated NK 
cells could also induce resistance of X02GB to NK cell-mediated lysis, but the decrease was 
significantly less when compared to that induced with split anergized NK cell supernatants 
(data not shown). Supernatants from untreated NK cells had no effect (Fig. 2a).
To examine the mechanisms by which X02GB cells became resistant by split anergized NK 
supernatants, we measured NK cell cytotoxicity when X02GB cells were treated with 
supernatants from split anergized NK cells, with and without anti-IFN-γ and/or anti-TNF-α 
antibodies. Treatment with anti-TNF-α antibody was not able to restore cytotoxicity, 
whereas addition of anti-IFN-γ antibody restored NK cell cytotoxicity to the levels obtained 
by non-differentiated X02GB. The combination of anti-IFN-γ and anti-TNF-α blocked NK 
cell-mediated differentiation of X02GB’s significantly and increased their sensitivity to NK 
cell cytotoxicity (Fig. 2a). The restoration of cytotoxicity against X02GB after treatment 
with split anergized NK supernatants in the presence of anti-IFN-γ antibody alone or the 
combination of anti-IFN-γ and anti-TNF-α antibodies could be observed when IL-2-treated 
NK cells were used to determine cytotoxicity (Fig. 2a). Treatment of X02GB with the 
combination of anti-TNF-α and anti-IFN-γ in the absence of NK cells supernatants had no 
effect on NK cell cytotoxicity (Fig. 2a).
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Increased expression of CD54 and MHC-I on X02GB was observed after treatment with 
supernatants collected from split anergized NK cells
We then assessed the expression of key cell surface receptors on X02GB after differentiation 
with supernatants from split anergized NK cells. As shown in Fig. 2b, the expression of 
CD54 and MHC-I increased substantially on X02GB after the addition of supernatants from 
split anergized NK cells and CD44, CD54 and MHC-I expression levels were found to 
significantly correlate with the resistance of NK supernatant-differentiated X02GB (Fig. 2b). 
Untreated NK cell supernatants did not change the surface expression on X02GB (Fig. 2b). 
The combination of anti-TNF-α and anti-IFN-γ antibodies prevented the upregulation of 
CD54 and MHC-I on X02GB to X02GB before treatment with split anergized NK 
supernatants (Fig. 2b). Anti-TNF-α was able to inhibit CD54 and MHC-I increase partially 
on split-anergized NK supernatant-treated X02GB, whereas anti-IFN-γ was able to block 
the increase in CD54 and MHC-I surface receptors completely (Fig. 2b).
We have previously shown that monocytes are able to induce split anergy in NK cells; 
therefore, we determined the expression of CD54, B7H1 and MHC-I on X02GB treated with 
supernatants from split anergized NK cells, cultured with irradiated monocytes (Fig. 3a). 
The addition of supernatants from irradiated monocytes in the absence of NK cells did not 
change the CD54, B7H1 and MHC-I surface expression on GBM (Fig. 3a) and OSCSCs 
(data not shown). However, when supernatants from monocytes cultured with split anergized 
NK cells were added to X02GB (Fig. 3a), or OSCSCs [10], a synergistic increase in the 
expression of all three receptors was observed. Accordingly, OSCSCs lost sensitivity and 
acquired resistance to NK cell-mediated cytotoxicity (Supplementary Fig. S2A) and [10].
We next determined cell numbers of X02GB after treatment with NK supernatants by 
microscopic evaluation (Fig. 3b, left) and the levels of cell death by staining with PI 
followed by flow cytometric analysis (Fig. 3b, right). As shown in Fig. 3b, a decrease in the 
numbers of X02GB was observed after their culture with split anergized NK cell 
supernatants when compared to untreated X02GB or those treated with untreated NK cell 
supernatants (Fig. 3b, left). The highest decrease was observed when X02GB was treated 
with the supernatants from split anergized NK cells cultured with monocytes (data not 
shown). The addition of anti-TNF-α antibody in the presence of split anergized NK 
supernatants increased the numbers of X02GB compared to X02GB treated with split 
anergized NK cells, and anti-IFN-γ or the combination of anti-TNF-α and anti-IFN-γ 
antibodies restored the numbers of cells to the levels observed with untreated X02GB (Fig. 
3b, left). In addition, low/no cell death could be observed in X02GB treated with the 
supernatants from split anergized NK cells in the absence or presence of irradiated 
monocytes (Fig. 3b, right).
Although treatment of X02GB with supernatants from split anergized NK cells was able to 
inhibit NK cell cytotoxicity, it increased IL-6 and IL-8 secretion by GBM while inhibiting 
IFN-γ secretion in co-cultures of NK cells with tumor cells
We have previously shown that OSCSCs treated with supernatants from split anergized NK 
cells inhibited NK cell cytotoxicity, increased CD54 and MHC-I and blocked secretion of 
cytokines and chemokines significantly [10] (Supplementary Figs. S1, S2). Although split 
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anergized NK cell supernatant-differentiated X02GB cultured with IL-2-treated NK cells 
had significant inhibitory effect on IFN-γ secretion (Fig. 4a), it resulted in a significant 
increase in IL-6 and IL-8 secretion when compared to either untreated X02GB, split 
anergized NK cell supernatant-differentiated X02GB treated with anti-IFN-γ and anti-TNF-
α or X02GB treated with supernatants from untreated NK cells (Fig. 4a).
Therefore, increase in IL-8 and IL-6 after differentiation of X02GB with split anergized NK 
supernatants is mediated by either TNF-α or IFN-γ since blocking of either cytokine or both 
together inhibited increased secretion of IL-6 and IL-8 (Fig. 4a). In addition, increased 
secretion of IL-8 and IL-6 could be seen in split anergized NK cell supernatant-differentiated 
X02GB regardless of whether they were cultured with or without untreated or IL-2-treated 
NK cells. Pre-treatment of X02GB with untreated NK supernatants slightly inhibited IFN-γ, 
IL-6 and IL-8 secretion (Fig. 4a). Thus, differentiation of X02GB with split anergized NK 
cell supernatants had a significant inhibitory effect on IFN-γ secretion by IL-2-treated NK 
cells, while it upregulated IL-6 and IL-8 secretion by glioma tumors in the presence or 
absence of their co-cultures with NK cells (Fig. 4a).
We then assessed the levels of TNFR I and II and IFN-γRα and IFN-γRβ on X02GB and 
compared the levels to those expressed on OSCSCs. We aimed to determine whether the 
magnitude of functional differences observed in differentiation could relate to the lower 
expression of these receptors on X02GB. As shown in Fig. 4b, receptor levels were lower on 
X02GB than on OSCSCs (Fig. 4b, Supplementary Fig. S3). Differentiation with split 
anergized NK cell supernatants decreased the levels of TNFR I, largely, TNFR II and IFN-
γRβ moderately on OSCSCs (Supplementary Fig. S3A), but not on X02GB cells (Fig. 4b). 
Similarly, addition of both rTNF-α and rIFN-γ to OSCSCs decreased the levels of TNFR I 
and IFN-γRβ largely, and TNFR II moderately, but not IFN-γRα (Supplementary Fig. 
S3B).
Differentiation of GBM by split anergized NK cell supernatants is independent of the 
effects mediated by IL-6 and IL-8
To determine whether secreted IL-6 or IL-8 by split anergized NK supernatant-differentiated 
tumors had any contributory effect on tumor differentiation, antibodies to each cytokine 
alone or to both cytokines together were added during differentiation, and the effect on NK 
cell-mediated cytotoxicity and expression of differentiation antigens on glioma cells were 
determined. As shown in Fig. 5, unlike anti-IFN-γ/anti-TNF-α, addition of anti-IL-6 and/or 
anti-IL-8 antibodies neither changed the resistance of differentiated X02GB (Fig. 5a) or 
X01GB (Fig. 5b) to NK cell-mediated cytotoxicity nor modulated MHC-I and CD54 
differentiation antigen levels expressed on these tumor cells (Fig. 5c, d, respectively). 
X01GB, another GBM CSCs/undifferentiated tumor, previously characterized by surface 
marker expression and ability to form tumors in mouse brain [35, 39], was found to be less 
susceptible to NK cell-mediated cytotoxicity (Fig. 5b) when compared to X02GB (Fig. 5a). 
In contrast to anti-IFN-γ/anti-TNF-α antibodies that blocked upregulation of differentiation 
antigen expression on glioma cells during differentiation with split anergized NK 
supernatants (Fig. 2b), no significant change of MHC class I and CD54 expression was 
observed in X02GB differentiated with split anergized NK super-natants with or without 
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anti-IL-6 and anti-IL-8 antibodies (Fig. 5d). Furthermore, no correlation was observed with 
the levels of NK cell cytotoxicity (Fig. 5a, d). The levels of CD54 fluctuated on X01GB 
depending on the specific antibody treatment (Fig. 5c), and no correlation could be found 
with the levels of NK cell cytotoxicity (Fig. 5b). The addition of hrIL-6 and/or hrIL-8 to 
untreated X02GB did not significantly affect cytotoxicity (Fig. 5e), and no correlation could 
be found with the levels of differentiation antigens on X02GB and X01GB (Fig. 5f). Thus, 
unlike IFN-γ and TNF-α, which drive split anergized NK supernatant-mediated 
differentiation of CSCs/poorly differentiated GBM cells, IL-6 and IL-8 did not contribute to 
the differentiation process.
Lack of MICA, ULBP (1–6) and KLRG1 NK cell ligand modulation on differentiated X02GB
We determined the levels of NK cell ligands on untreated and split anergized NK 
supernatant-differentiated X02GB. Although both CD54 and MHC class I were significantly 
increased on NK-differentiated X02GB, no or a very slight decrease in MICA, ULBP (1–6) 
and KLRG1 could be observed on these tumors (Fig. 6).
Discussion
The stage of differentiation of many tumors including GBM is predictive of their sensitivity 
to NK cell lysis since CSCs/poorly differentiated GBM tumors are targets of NK cells, 
whereas those differentiated with split anergized NK cell supernatants display resistance to 
NK cell-mediated cytotoxicity [32, 41–46]. We have shown that NK cells play a significant 
role in differentiation of tumors by providing critical signals via secreted IFN-γ and TNF-α, 
as well as direct cell–cell contact [10, 35]. Furthermore, tumor differentiation is likely 
supported by signals from other immune effectors, such as monocytes and macrophages 
within the tumor stroma to induce split anergy in NK cells [41, 43–46]. Interestingly, 
significantly higher amounts of NK supernatant containing IFN-γ were required to 
differentiate X02GB in comparison with OSCSCs resulting in tumor growth inhibition, 
upregulation of CD54, B7H1 and MHC-I expression and resistance to NK cell-mediated 
cytotoxicity. Moreover, tumor differentiation by split anergized NK cell supernatants also 
inhibited cytokine and chemokine secretion in the cultures of NK cells with OSCSCs. In 
contrast, treatment of X02GB with split anergized NK supernatants significantly inhibited 
NK cell cytotoxicity and decreased IFN-γ secretion, whereas it had the opposite effect on 
IL-6 and IL-8 production. Additionally, although high amounts of split anergized NK cell 
supernatants triggered cell death in OSCSCs [10], supernatants containing higher levels of 
IFN-γ were unable to induce cell death in X02GB. These experiments revealed distinct 
responses of GBM and oral tumors to NK cell-mediated differentiation, which could likely 
be one of the underlying mechanisms for GBM’s aggressive behavior and poor prognosis in 
patients. GBM tumor cells may survive because of (1) the inability of NK cells to lyse the 
tumors through granzyme/perforin pathway, and (2) they may resist cell death induced by 
death inducing cytokines such as TNF-α and Fas ligand.
GBM may remain persistently inflammatory since upon differentiation with split anergized 
NK cell supernatants they increase, rather than decrease, inflammatory cytokine and 
chemokine IL-6 and IL-8. IL-6 is known to favor the survival of CSCs [47]. Lack of cell 
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death and decreased ability to control the release of inflammatory IL-6 and IL-8 in X02GB 
differentiated with split anergized NK supernatants correlate with the lower surface 
expression and function of TNF-α and IFN-γ receptors. OSCSCs express much higher 
levels of TNFRI and IFN-γRα and IFN-γRβ when compared to X02GB. Accordingly, upon 
differentiation with split anergized NK supernatants or treatment with rTNF-α and/or rIFN-
γ, OSCSCs down-modulate both TNFRI and IFN-γRβ. This suggests an increased receptor 
signaling and function, whereas no such changes are observed for X02GB. Therefore, 
strategies to augment both TNF-α and IFN-γ receptor levels on GBM cells may be effective 
in controlling these tumors.
GBM patients are likely to benefit from NK cell adoptive therapy since NK cells are capable 
of eliminating CSCs. In this regard, depletion of NK split anergizing effectors, such as 
monocytes, in patients before NK cell transplantation should provide such a strategy for NK 
cells to target GBM CSCs. However, this approach may also decrease the ability of NK cells 
to secrete cytokines and chemokines due to the removal of the synergizing effect of 
monocytes with NK cells for the secretion of TNF-α and IFN-γ [42]. Interestingly, 
secretion of TNF-α and IFN-γ by split anergized NK cells is responsible for the increased 
induction and secretion of inflammatory cytokines and chemokines by NK-differentiated 
X02GB. This mechanism differs remarkably from NK cell-differentiated oral, lung and 
pancreatic tumor cells in which a significant reduction rather than upregulation of 
inflammatory cytokines by those tumors was observed (Supplementary Fig. S1 and data not 
shown). Therefore, this effect appears to be very specific to GBM. Indeed, in previous 
reports it was suggested that glioma cells may increase the expression of 
immunosuppressive cytokines in response to an increased lymphocyte infiltration in the 
tumor stroma, which is in agreement with our findings [48].
Tumor differentiation by split anergized NK cell supernatants containing TNF-α and IFN-γ 
was not only responsible for the decrease in inflammatory cytokines and chemokines in oral 
and pancreatic tumor cells, but it also inhibited tumor invasion and metastasis in animals 
(Supplementary Fig. S2B and manuscript in preparation). However, since GBM 
differentiation with split anergized NK cell supernatants elevated the inflammatory cytokine 
IL-6 and chemokine IL-8, it may pose a challenge for tumor therapy. It is unclear, why GBM 
behaves differently from other tumors with regard to their responses to differentiation by NK 
cell supernatants. However, considering the elevated inflammatory index in patients with 
GBM and its possible underlying role in cancer progression, strategies for 
immunotherapeutics should be designed to retain the tumor killing function as well as IFN-γ 
secretion by the NK cells, while suppressing tumor-induced IL-6 and IL-8 secretion. 
Moreover, most studies in GBM patients reveal an immunosuppressive tumor micro-
environment [49, 50]. Since NK supernatant-differentiated GBM cells decreased IFN-γ 
secretion by the NK cells while increasing IL-6 and IL-8 secretion by the tumor cells, these 
studies closely resemble those obtained from the clinical data of GBM patients [49, 50] and 
thus can provide an important preclinical model to study the mechanisms for 
immunosuppression in GBM patients.
Increased IL-8 induction in glioma also occurs in response to hypoxia, Fas ligation, death 
receptor activation, cytosolic Ca2+ and cytokines [5]. Thus, we tested the ability of secreted 
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IL-6 and/or IL-8 from NK-differentiated GBM cells to modulate differentiation of CSCs/
poorly differentiated GBM. Unlike antibodies to IFN-γ and/or TNF-α, which blocked 
differentiation of tumors with supernatants from split anergized NK cells, addition of anti-
IL-6 and/or anti-IL-8 during differentiation neither changed resistance of X02GB or X01GB 
against NK cell cytotoxicity, nor significantly modified expression of differentiation 
antigens, indicating the lack of contribution of IL-6 and/or IL-8 to differentiation of GBM by 
NK cell supernatants. Furthermore, unlike rIFN-γ and/or rTNF-α, which significantly 
upregulated the expression of differentiation antigens CD54 or MHC-I on OSCSCs [10], the 
addition of rIL-6 and/or rIL-8 to X02GB or X01GB did not cause significant changes in the 
expression of differentiation antigens.
No significant differences could be seen in the expression of MICA, ULBP (1–6) and 
KLRG1 ligands on NK-differentiated X02GB when compared to untreated tumors. These 
results indicated that these ligands might not play a role in the loss of NK cytotoxicity 
observed when tumors are differentiated with supernatants from split anergized NK cells.
Emerging data suggest that differentiated GBM cells may revert to their stem-like stage and 
thus supply the pool of stem cells for the continuous growth of the GBM tumors (Dr. Inder 
Verma, Salk Institute; personal communication). The induction of pro-differentiation 
cytokines such as IFN-γ and TNF-α by the effector NK cells may likely keep the GBM 
tumors in a differentiated state, thereby limiting its growth. However, if NK cells within the 
tumor micro-environment lose their ability to secrete IFN-γ, GBM cells may revert to their 
stem-like stage and fuel tumor growth. Indeed, within 2 weeks of removal of NK cell 
supernatants from differentiated OSCSCs, all tumor cells were found to revert to their stem-
like stage [10].
Considering that NK-differentiated tumors are highly susceptible to chemotherapy, whereas 
their stem-like tumors are highly resistant, the combination of NK cell immunotherapy and 
chemotherapy may be effective in the treatment of GBM patients [10, 51, 52]. The most 
troubling outcome of GBM to overcome when considering therapies is the ability to deplete 
cytotoxic NK cells due to their immunosuppressive effect. In this case, the expansion of 
CSCs is not kept under control by the NK cells, resulting in their invasion, metastasis and 
the progression of cancer.
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hr Human recombinant
IFN-γR Interferon-γ receptor
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Fig. 1. 
X02GB cells were more susceptible to NK cells and triggered higher levels of IFN-γ than 
U87. Highly purified NK cells (1 × 106 cells/mL) were either left untreated or treated with 
IL-2 (1000 units/mL) or anti-CD16mAb (3 μg/mL) or a combination of IL-2 (1000 
units/mL) and anti-CD16mAb (3 μg/mL) (condition to induce split anergy) for 12–24 h and 
used in cytotoxicity assay against U87 GBM and X02GB CSCs. NK cell cytotoxicity was 
determined using a standard 4-h 51Cr release assay. One of the three representative 
experiments is shown in this figure (a). NK cells were treated as described in (a), and each 
NK cells sample (1 × 105/mL) was either cultured in the absence or presence of U87 and 
X02GB cells at an NK to GBM ratio of 0.5:1. After an overnight culture, supernatants were 
removed from the cultures and the levels of IFN-γ secretion were determined using specific 
ELISA (b). One of the two representative experiments is shown in this figure
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Fig. 2. 
Increased resistance to NK cell-mediated cytotoxicity and increased expression of CD54 and 
MHC-I on X02GB differentiated with supernatants from split anergized NK cells. Highly 
purified NK cells were left untreated or treated with IL-2 and anti-CD16mAb for 24 h, after 
which the supernatants were used for differentiation of X02GB cells as described in 
“Materials and methods” section. Untreated X02GB and those treated with anti-TNF-α 
(1:100) and anti-IFN-γ (1:100) in the absence of NK cell supernatants were also used as 
controls. Similar amounts of supernatants from untreated NK cells and those cultured with 
split anergized NK cells in the presence and absence of anti-TNF-α (1:100) and/or anti-IFN-
γ (1:100) were used to treat X02GB for a period of 7 days to induce differentiation. 
Afterward, the cells were used in a standard 51Cr release assay against freshly isolated 
untreated IL-2 (1000 units/mL) or the combination of IL-2 (1000 units/mL) and anti-
CD16mAb (3 μg/mL)-treated NK cells (a). X02GB was differentiated with NK supernatants 
in the presence and absence of anti-TNF-α and anti-IFN-γ antibodies as described in (a), 
and then, CD54, CD44 and MHC-I surface expression on untreated and split anergized NK 
cell supernatant-treated cells was assessed after PE-conjugated antibody staining followed 
by flow cytometric analysis. Isotype control antibodies were used as controls. The numbers 
in the right-hand corner are the percentages and the mean channel fluorescence intensities in 
each histogram (b)
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Fig. 3. 
Monocytes induced split anergy in NK cells. NK cells were treated with a combination of 
IL-2 (1000 units/mL) and anti-CD16mAb (3 μg/mL) to induce split anergy and subsequently 
cultured with autologous monocytes at 1:1 (NK:monocytes) ratio for 18–24 h. Monocytes 
were treated with IL-2 (1000 units/mL) and anti-CD16mAb (3 μg/mL) for 18–24 h and used 
as control. Afterward, supernatants from split anergized NK cells and monocytes were 
harvested and added to X02GB for 7 days. Surface expression of CD54, B7H1 and MHC-I 
was assessed after PE-conjugated antibody staining followed by flow cytometric analysis. 
Isotype control antibodies were used as controls. The numbers in the right-hand corner are 
the percentages and the mean channel fluorescence intensities in each histogram (a). At the 
end of the incubation of X02GB with split anergized NK cell supernatants, X02GB cells, 
which remained attached to the plate during the incubation period, were collected and the 
number of cells was assessed using microscopy (b, left). After X02GB was differentiated 
with split anergized NK cell supernatants, as described in (a), the percentage of cell death 
was assessed with propidium iodide staining followed by cytometric analysis. The number in 
the right-hand corner is the percentage for each histogram (b, right)
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Fig. 4. 
X02GB differentiated by split anergized NK cell supernatants inhibited IFN-γ secretion but 
triggered increased IL-8 and IL-6 secretion by NK cells. NK cells were left untreated or 
treated with a combination or IL-2 (1000 units/mL) and anti-CD16mAb (3 μg/mL) in the 
presence of anti-TNF-α (1:100), anti-IFN-γ (1:100) or a combination of anti-TNF-α 
(1:100) and anti-IFN-γ (1:100) for 18 h. Afterward, supernatants were used to differentiate 
X02GB as described in “Materials and methods” section. Freshly isolated NK cells were left 
untreated or treated with IL-2 (1000 units/mL) for 18 h. Afterward, NK cells were added to 
X02GB treated with split anergized NK cell supernatants at an effector to target ratio of 0.5–
1. After an overnight incubation, the supernatants were removed from the co-cultures and 
the levels of IFN-γ, IL-8 and IL-6 secretions were determined using specific ELISAs (a). 
Untreated and split anergized NK supernatant-differentiated X02GB cells were prepared as 
described in “Materials and methods” section, and the levels of TNFRI, TNFRII, IFN-γRα 
and IFNγRβ on X02GB cells were determined using PE-conjugated antibodies followed by 
flow cytometric analysis. The histogram on the left is the isotype control staining and on the 
right the receptor staining. The numbers in the right-hand corner are the percentage of 
positive cells and the mean channel fluorescence intensity for each receptor expression (b)
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Fig. 5. 
Differentiation of GBM by split anergized NK cell supernatants was independent of the 
effects of IL-6 and IL-8. X01GB (b) and X02GB (a) cells were differentiated with split 
anergized NK cell supernatants as described in “Materials and methods” section in the 
presence or absence of anti-IL-6 (1:100), anti-IL-8 (1:100) or a combination of anti-IL-6 
(1:100) and anti-IL-8 (1:100). Afterward, the cells were used in a standard 51Cr release 
assay against freshly isolated NK cells treated overnight with IL-2 (1000 units/mL) or the 
combination of IL-2 (1000 units/mL) and anti-CD16mAb (3 μg/mL) (a, b). Untreated and 
split anergized NK supernatant-differentiated X01 and X02GB cells were prepared as 
described in (a, b), and the levels of MHC-I and CD54 on X01GB (c) and X02GB (d) were 
determined using PE-conjugated antibodies followed by flow cytometric analysis. The 
number in the upper right-hand corner of each histogram is the mean channel fluorescence 
intensity for each receptor expression (c, d). X02GB cells were plated and then treated with 
hrIL-6 (8 ng/mL), hrIL-8 (8 ng/mL) or a combination of hrIL-6 (8 ng/mL) and hrIL-8 (8 
ng/mL) for 24 h. Afterward, the cells were used in a standard 51Cr release assay against 
freshly isolated NK cells treated overnight with IL-2 (1000 units/mL) (e). Untreated and 
split anergized NK supernatant-differentiated X01 and X02GB cells were prepared as 
described in (e), and the levels of MHC-I and CD54 on X01 and X02GB were determined 
using PE-conjugated antibodies followed by flow cytometric analysis. The number in the 
upper right-hand corner of each histogram is the mean channel fluorescence intensity for 
each receptor expression (f)
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Fig. 6. 
NK cell ligand expression on untreated and split anergized NK cell supernatant-
differentiated X02GB. X02GB cells were differentiated with split anergized NK cell 
supernatants as described in “Materials and methods” section. Untreated X02GB was used 
as control. Afterward, the cells were washed with 1× PBS, detached from the tissue culture 
plate and surface expression of CD54, MHCI, MICA, KLRG1 and ULBP 1–6 was assessed 
after PE-conjugated antibody staining followed by flow cytometric analysis. The number in 
the upper right-hand corner of each histogram is the mean channel fluorescence intensity for 
each receptor expression
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